Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 October 2004Website:
http://www.inva.comNext earnings report:
02 August 2024Last dividends:
08 September 2015Next dividends:
N/APrice
after hours | Tue, 02 Jul 2024 20:25:39 GMTDividend
Analysts recommendations
Institutional Ownership
INVA Latest News
Zai Lab Limited and Innoviva Specialty Therapeutics have received approval from China's NMPA for Zai Lab's NDA for XACDURO® (sulbactam-durlobactam) for the treatment of HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus comp.
Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been a lot of movement at the company over the past 12-18 months on myriad fronts.
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What type of business is Innoviva?
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
What sector is Innoviva in?
Innoviva is in the Healthcare sector
What industry is Innoviva in?
Innoviva is in the Biotechnology industry
What country is Innoviva from?
Innoviva is headquartered in United States
When did Innoviva go public?
Innoviva initial public offering (IPO) was on 05 October 2004
What is Innoviva website?
https://www.inva.com
Is Innoviva in the S&P 500?
No, Innoviva is not included in the S&P 500 index
Is Innoviva in the NASDAQ 100?
No, Innoviva is not included in the NASDAQ 100 index
Is Innoviva in the Dow Jones?
No, Innoviva is not included in the Dow Jones index
When does Innoviva report earnings?
The next expected earnings date for Innoviva is 02 August 2024